In the POPLAR trial, second-line, NSCLC patients with PD-L1 IHC SP142 expression ≥ 1% in either tumor or immune cells had significantly better overall survival when treated with atezolizumab monotherapy versus docetaxel (median 15.5 months versus 9.2 months, p = 0.005) [28]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.